Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23696528 | 1.00 | MEN1 (0.45) | MEN1KMT2ASMN1; SMN2GAARAB9A | |
| SCHEMBL25477658 | 0.86 | MEN1 (0.46) | MEN1KMT2ASMN1; SMN2GAARAB9A | |
| SCHEMBL24379955 | 0.86 | MEN1 (0.46) | MEN1KMT2ASMN1; SMN2GAARAB9A | |
| SCHEMBL23696416 | 0.86 | MEN1 (0.46) | MEN1KMT2ASMN1; SMN2GAARAB9A | |
| SCHEMBL25698945 | 0.84 | MEN1 (0.43) | MEN1KMT2ASMN1; SMN2GAARAB9A | |
| SCHEMBL25654240 | 0.83 | MEN1 (0.46) | MEN1KMT2ASMN1; SMN2GAARAB9A | |
| SCHEMBL22793879 | 0.80 | MEN1 (0.50) | MEN1KMT2ASMN1; SMN2HSD17B10TSHR | |
| SCHEMBL25913675 | 0.80 | MEN1 (0.50) | MEN1KMT2ASMN1; SMN2HSD17B10TSHR | |
| SCHEMBL23560063 | 0.80 | MEN1 (0.50) | MEN1KMT2ASMN1; SMN2HSD17B10TSHR | |
| SCHEMBL25477056 | 0.79 | MEN1 (0.54) | MEN1KMT2ASMN1; SMN2MAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MEN1 4055/4885KMT2A 445/4885SMN1; SMN2 2647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.